Asia · Regional markets · Vietnam Investment Review

Mabwell presents Phase II trial results for breast cancer drug 9MW2821

Published by Vietnam Investment Review · Vietnam 9 h ago

Biopharmaceutical firm Mabwell scheduled Phase II clinical trial data presentations for its Nectin-4-targeting antibody-drug conjugate 9MW2821 at the European Society for Medical…

Read the full article on Vietnam Investment Review Sign in to save

MarketNews shows the headline and summary published by the outlet. The full article is on the publisher's website. (vir.com.vn)

Also worth reading

Mint

Jio Platforms IPO draws ₹8,110 crore in anchor investor bids

CNBC-TV18

Varmora Granito Q2 results: Profit more than triples to ₹44 crore, revenue rises 9%

Business Standard

Tonbo Imaging India IPO subscribed nearly 136 times, led by QIB demand

The Business Times

Mi Material focusing on ‘things that we can control’ as it launches S$215 million SGX IPO

Tech in Asia

YouTrip restores services after vendor glitch causes outage

The Straits Times Business